|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 6 (March 15), 2000:
pp. 1918-1924
Impact of bone marrow transplantation for symptomatic sickle cell
disease: an interim report
Mark C. Walters,
Rainer Storb,
Melinda Patience,
Wendy Leisenring,
Terri Taylor,
Jean E. Sanders,
George E. Buchanan,
Zora R. Rogers,
Patricia Dinndorf,
Sally C. Davies,
Irene A. G. Roberts,
Rosarita Dickerhoff,
Andrew
M. Yeager,
Lewis Hsu,
Joanne Kurtzberg,
Kwaku Ohene-Frempong,
Nancy Bunin,
Francoise Bernaudin,
Wing-Yen Wong,
J. Paul Scott,
David Margolis,
Elliott Vichinsky,
Donna A. Wall,
Allen S. Wayne,
Charles Pegelow,
Rupa Redding-Lallinger,
Joseph Wiley,
Martin Klemperer,
William C. Mentzer,
Franklin O. Smith, and
Keith M. Sullivan for the Multicenter
Investigation of Bone Marrow Transplantation for Sickle Cell Disease
From the Fred Hutchinson Cancer Research Center, Seattle, WA;
University of Washington, Seattle, WA; University of Texas Southwestern
Medical Center, Dallas, TX; Children's Hospital National Medical
Center and George Washington University, Washington, DC; Royal
Postgraduate Medical School, London, U.K.; University of Bonn, Sankt
Augustin, Germany; Emory University, Atlanta, GA; Duke University,
Durham, NC; Children's Hospital of Philadelphia and University of
Pennsylvania, Philadelphia, PA; Hospital Henri Mondor, Creteil, France,
University of Southern California, Los Angeles, CA; Children's
Hospital of Wisconsin and Medical College of Wisconsin, Milwaukee, WI;
Children's Hospital of Oakland, Oakland, CA; St. Louis University, St.
Louis, MO; University of Miami, Miami, FL; University of North
Carolina, Chapel Hill, NC; University of South Florida, St. Petersburg,
FL; University of California, San Francisco, CA; and the Indiana
University School of Medicine, Indianapolis, IN.
Fifty children who had symptomatic sickle cell disease received
matched sibling marrow allografts between September 1991 and March
1999, with Kaplan-Meier probabilities of survival and event-free survival of 94% and 84%, respectively. Twenty-six patients (16 male,
10 female) had at least 2 years of follow-up after transplantation and
were evaluated for late effects of transplantation and for its impact
on sickle cell-related central nervous system (CNS) and pulmonary
disease. Patients ranged between 3.3 and 14.0 (median, 9.4) years of
age and had a median follow-up of 57.9 (range 38-95) months after
transplantation. Among 22 of 26 patients who had stable donor
engraftment, complications related to sickle cell disease resolved, and
none experienced further episodes of pain, stroke, or acute chest
syndrome. All 10 engrafted patients with a prior history of stroke had
stable or improved cerebral magnetic resonance imaging results.
Pulmonary function tests were stable in 22 of the 26 patients, worse in
two, and not studied in two. Seven of eight patients transplanted for
recurrent acute chest syndrome had stable pulmonary function. Linear
growth measured by median height standard deviation score improved from
 0.7 before transplantation to 0.2 after transplantation. An
adverse effect of busulfan conditioning on ovarian function was
demonstrated in five of seven evaluable females who are currently at
least 13 years of age. None of the four males tested had elevated serum gonadotropin levels. These data confirm that allogenic bone marrow transplantation establishes normal erythropoiesis and is associated with improved growth and stable CNS imaging and pulmonary function in
most patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Monagle, E. Chalmers, A. Chan, G. deVeber, F. Kirkham, P. Massicotte, and A. D. Michelson
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
887S - 968S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Bailey Jr, F. D. Armstrong, A. R. Kemper, D. Skinner, and S. F. Warren
Supporting Family Adaptation to Presymptomatic and "Untreatable" Conditions in an Era of Expanded Newborn Screening
J. Pediatr. Psychol.,
March 30, 2008;
(2008)
jsn032v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Fitzhugh, S. Perl, and M. M. Hsieh
Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD)
Blood,
February 1, 2008;
111(3):
1742 - 1743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mazumdar, M. M. Heeney, C. M. Sox, and T. A. Lieu
Preventing Stroke Among Children With Sickle Cell Anemia: An Analysis of Strategies That Involve Transcranial Doppler Testing and Chronic Transfusion
Pediatrics,
October 1, 2007;
120(4):
e1107 - e1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bernaudin, G. Socie, M. Kuentz, S. Chevret, M. Duval, Y. Bertrand, J.-P. Vannier, K. Yakouben, I. Thuret, P. Bordigoni, et al.
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Blood,
October 1, 2007;
110(7):
2749 - 2756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Lee, S. Piomelli, S. Granger, S. T. Miller, S. Harkness, D. J. Brambilla, R. J. Adams, and for the STOP Study Investigators
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results
Blood,
August 1, 2006;
108(3):
847 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Villella
STOP 2 Makes the Case for NOT Stopping Transfusions
AAP Grand Rounds,
May 1, 2006;
15(5):
54 - 55.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. S. Platt
Prevention and Management of Stroke in Sickle Cell Anemia
Hematology,
January 1, 2006;
2006(1):
54 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Optimizing Primary Stroke Prevention in Sickle
Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
N. Engl. J. Med.,
December 29, 2005;
353(26):
2769 - 2778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Walters
Stem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy
Hematology,
January 1, 2005;
2005(1):
66 - 73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Kean, E. A. Manci, J. Perry, C. Balkan, S. Coley, D. Holtzclaw, A. B. Adams, C. P. Larsen, L. L. Hsu, and D. R. Archer
Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease
Blood,
December 15, 2003;
102(13):
4582 - 4593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Claster and E. P Vichinsky
Managing sickle cell disease
BMJ,
November 15, 2003;
327(7424):
1151 - 1155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Deymann and K. K. Goertz
Myocardial Infarction and Transient Ventricular Dysfunction in an Adolescent With Sickle Cell Disease
Pediatrics,
February 1, 2003;
111(2):
e183 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Emery, E. Yannaki, J. Tubb, T. Nishino, Q. Li, and G. Stamatoyannopoulos
Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma -globin gene silencing in vivo
Blood,
August 28, 2002;
100(6):
2012 - 2019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Section on Hematology/Oncology and Committee on Ge
Health Supervision for Children with Sickle Cell Disease
Pediatrics,
March 1, 2002;
109(3):
526 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Kean, M. M. Durham, A. B. Adams, L. L. Hsu, J. R. Perry, D. Dillehay, T. C. Pearson, E. K. Waller, C. P. Larsen, and D. R. Archer
A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation
Blood,
March 1, 2002;
99(5):
1840 - 1849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Walters, A. W. Nienhuis, and E. Vichinsky
Novel Therapeutic Approaches in Sickle Cell Disease
Hematology,
January 1, 2002;
2002(1):
10 - 34.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Iannone, L. Luznik, L. W. Engstrom, S. L. Tennessee, F. B. Askin, J. F. Casella, T. S. Kickler, S. N. Goodman, A. L. Hawkins, C. A. Griffin, et al.
Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia
Blood,
June 15, 2001;
97(12):
3960 - 3965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. FEINSTEIN, B. SANDMAIER, D. MALONEY, P. A. McSWEENEY, M. MARIS, C. FLOWERS, J. RADICH, M.-T. LITTLE, R. A. NASH, T. CHAUNCEY, et al.
Nonmyeloablative Hematopoietic Cell Transplantation: Replacing High-Dose Cytotoxic Therapy by the Graft-versus-Tumor Effect
Ann. N.Y. Acad. Sci.,
June 1, 2001;
938(1):
328 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Adams
Stroke Prevention and Treatment in Sickle Cell Disease
Arch Neurol,
April 1, 2001;
58(4):
565 - 568.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Krishnamurti, B. R. Blazar, and J. E. Wagner
Bone Marrow Transplantation without Myeloablation for Sickle Cell Disease
N. Engl. J. Med.,
January 4, 2001;
344(1):
68 - 68.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Adams, K. Ohene-Frempong, and W. Wang
Sickle Cell and the Brain
Hematology,
January 1, 2001;
2001(1):
31 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Sullivan, R. Parkman, and M. C. Walters
Bone Marrow Transplantation for Non-Malignant Disease
Hematology,
January 1, 2000;
2000(1):
319 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
